Vistagen Therapeutics (VTGN) Change in Accured Expenses (2010 - 2026)

Vistagen Therapeutics has reported Change in Accured Expenses for 17 years, with the latest figure at -$243000.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 108.22% year-over-year to -$243000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $828000.0 (down 85.43% YoY) and the FY2026 annual result came in at $828000.0, down 85.43% from the prior year.
• Change in Accured Expenses declined to -$243000.0 in Q1 2026 per VTGN's latest filing, from $294000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.2 million in Q3 2025 and troughed at -$2.4 million in Q2 2025.
• A 5-year average of $329917.6 and a median of $269000.0 in 2023 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2024 and 2025: Change in Accured Expenses surged 635.32% in 2024, then sank 432.75% in 2025.
• Over 5 years, Change in Accured Expenses stood at -$1.5 million in 2022, then jumped by 118.4% to $269000.0 in 2023, then soared by 635.32% to $2.0 million in 2024, then sank by 85.14% to $294000.0 in 2025, then slumped by 182.65% to -$243000.0 in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$243000.0, $294000.0, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.